Coegin Pharma Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
3
- Stock Symbol
-
COEGIN
- Investments
-
1
- Share Price
-
$0.68
- (As of Monday Closing)
Coegin Pharma General Information
Description
Coegin Pharma AB is a biotechnology company that focuses on the development of small molecule therapies for the treatment of inflammatory diseases such as cancer and kidney disease.
Contact Information
Website
www.coeginpharma.com
Formerly Known As
Avexxin, GoldBlue AB
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NGM
Primary Office
- Medicon Village
- 223 81 Lund
- Sweden
+46 0000000000
Coegin Pharma Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.68 | $0.69 | $0.55 - $2.32 | $6.44M | 9.4M | 14.3K | -$0.35 |
Coegin Pharma Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 7,230 | 8,822 | 21,783 | 2,479 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (2,465) | (3,184) | (3,160) | (5,018) |
| Net Income | (2,734) | (3,474) | (3,161) | (5,015) |
| Total Assets | 2,238 | 2,804 | 3,352 | 2,334 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Coegin Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Coegin Pharma Patents
Coegin Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202117609-D0 | 2-oxothiazole compositions for treatment of t-cell acute lymphoblastic leukaemia | Inactive | 06-Dec-2021 | 0000000000 | |
| AU-2021416278-A1 | Actinic keratosis treatment | Pending | 31-Dec-2020 | 0000000000 | |
| GB-202020843-D0 | Actinic keratosis treatment | Inactive | 31-Dec-2020 | 0000000000 | |
| AU-2020316962-A1 | Phospholipase-a2 inhibitors for the prevention of cancer metastasis | Pending | 25-Jul-2019 | 0000000000 | |
| EP-4003316-A1 | Phospholipase-a2 inhibitors for the prevention of cancer metastasis | Pending | 25-Jul-2019 | A61K31/122 |
Coegin Pharma Executive Team (10)
Coegin Pharma Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bo Anders Ljungqvist | Self | Board Member | 000 0000 |
| Erlend Skagseth | Sarsia Management | Board Member | 000 0000 |
| Farzad Abdi-Dezfuli Ph.D | Sarsia Management | Board Member | 000 0000 |
| Jan Foss | Leiv Eiriksson Nyskaping | Board Member | 000 0000 |
| Niclas Lundqvist | Coegin Pharma | Board Member | 000 0000 |
Coegin Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Coegin Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Coegin Pharma Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 07-Feb-2022 | 0000000000 | Drug Discovery | 0000 0000 |
Coegin Pharma Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000000 | Drug Discovery | Lund, Sweden | 0000 |